The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000747325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
29/05/2026
Date registered
Help: Date registered
23/06/2026
Date last updated
Help: Date last updated
29/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
23/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Implementing an accessible self-management program for quality of life in people living with seizures.
Scientific title
Implementing an accessible self-management program for quality of life in people living with seizures: A randomised controlled trial compared to usual care [HOBSCOTCH Australia]
Additional trial identifiers [1] 316720 0
None
Universal Trial Number (UTN)
Trial acronym
HOBSCOTCH-AU
Related trial records

Health condition
Health condition(s) studied:
Epilepsy 340995 0
Condition category
Condition code
Neurological 337138 337138 0 0
Epilepsy

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The HOme Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH) program is an evidence-based self-management program for patients with epilepsy and subjective cognitive concerns. The HOBSCOTCH program comprises 8 weekly 1-hour sessions facilitated by a HOBSCOTCH-trained clinician (‘coach’) to guide participants through memory strategies and problem-solving techniques (i.e., Problem Solving Therapy) according to their own personalised goals. Examples of memory strategies include compensatory techniques (such as routines, reminders or mental associations) as well as lifestyle changes (such as relaxation or managing sleep and fatigue). For this study, HOBSCOTCH coaches will include nursing, psychology and other allied health professionals. All coaches will receive 8 hours of initial training plus an additional 2 hours of re-certification training after two years, delivered by Master Coaches at the HOBSCOTCH Institute for Cognitive Health and Wellbeing. Coaches will be trained or re-certified in the month prior to the first participant enrollment. HOBSCOTCH is delivered via telehealth (phone or video call). Standard care (i.e., treatment as usual) in epilepsy focuses primarily on seizure management and involves periodic reviews with the neurologist/epileptologist. The HOBSCOTCH program differs from standard care as the focus is on improving seizure self-management. Participants will be guided 1:1 through strategies and problem-solving therapy according to a structured program. They will also be provided with a program workbook and encouraged to use a diary to foster self-management with support from their HOBSCOTCH ‘coach’ (i.e., clinician-researcher delivering the intervention). The program workbook is a protected HOBSCOTCH resource available only to participants completing the HOBSCOTCH intervention, and is provided for use in this study by the HOBSCOTCH Institute for Cognitive Health and Wellbeing. Program adherence will be monitored via session attendance records. Intervention Group participants will also have full access to their usual ongoing clinical care with their neurologist/epileptologist, GP, psychologist and/or any other healthcare provider, including medications, psychotherapy, and clinical consultation/review, as individually indicated and arranged outside of the research trial.
Intervention code [1] 333409 0
Rehabilitation
Intervention code [2] 334359 0
Treatment: Other
Intervention code [3] 334360 0
Behaviour
Description of the comparator or control
This randomised control trial employs a 'treatment as usual' 24-week waitlist control condition.

Control group participants will have full access to their usual ongoing clinical care with their neurologist/epileptologist, GP, psychologist and/or any other healthcare provider, including medications, psychotherapy, and clinical consultation/review, as individually indicated and arranged outside of the research trial.

The possibility of being randomised into the study control group will be fully explained to patients as part of initial informed consent processes, and will not pose a barrier to patients accessing other services and supports related to epilepsy care during the trial. Although some patients may find this waitlist period unacceptable, it is important for the clear and interpretable evaluation of outcomes in relation to program effectiveness.
Control group
Active

Outcomes
Primary outcome [1] 344716 0
Quality of Life
Timepoint [1] 344716 0
Baseline, 6-weeks (mid-intervention), 12-weeks (post-intervention) [PRIMARY TIMEPOINT] and 24-weeks (follow-up)
Secondary outcome [1] 458972 0
Self-Efficacy
Timepoint [1] 458972 0
Baseline, 12-weeks (post-intervention) and 24-weeks (follow-up)
Secondary outcome [2] 458973 0
Everyday Cognitive functioning
Timepoint [2] 458973 0
Baseline, 12-weeks (post-intervention) and 24-weeks (follow-up)
Secondary outcome [3] 458974 0
Depression
Timepoint [3] 458974 0
Baseline, 12-weeks (post-intervention) and 24-weeks (follow-up)
Secondary outcome [4] 458975 0
Anxiety
Timepoint [4] 458975 0
Baseline, 12-weeks (post-intervention) and 24-weeks (follow-up)
Secondary outcome [5] 458976 0
Healthcare Utilisation
Timepoint [5] 458976 0
Monthly throughout the intervention from baseline to 24-weeks (follow-up).
Secondary outcome [6] 458977 0
Acceptability
Timepoint [6] 458977 0
12-weeks (post-intervention).
Secondary outcome [7] 458978 0
Objective Cognitive Functioning
Timepoint [7] 458978 0
Baseline and 24-weeks (follow-up).
Secondary outcome [8] 462262 0
Quality of Life
Timepoint [8] 462262 0
Baseline, 6-weeks (mid-intervention), 12-weeks (post-intervention) and 24-weeks (follow-up)
Secondary outcome [9] 462263 0
Quality of Life
Timepoint [9] 462263 0
Baseline, 6-weeks (mid-intervention), 12-weeks (post-intervention) and 24-weeks (follow-up)
Secondary outcome [10] 463123 0
Community Participation
Timepoint [10] 463123 0
Monthly throughout the intervention from baseline to 24-weeks (follow-up).

Eligibility
Key inclusion criteria
• Patients diagnosed with epilepsy or who have a history of epileptic seizures.
• Subjective memory problems or other cognitive concerns.
• Aged 18 years or older.
• Willingness to provide informed consent, and to participate and comply with the study requirements.
• Sufficient English language proficiency to engage in intervention and complete questionnaires.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Clinically diagnosed progressive neurological disease or dementia.
• Acute psychiatric or neurological illness.
• Current substance or alcohol misuse.
• Individuals experiencing non-epileptic seizures only (in the absence of concurrent epilepsy diagnosis).
• Intellectual disability (i.e., IQ<70).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is concealed (central randomisation via SLHD REDCap software).
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer-generated sequence (SLHD REDCap software).
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
We aim to recruit 160 patients over 24 months, allowing for ~25% attrition (based on rates in previous studies investigating comparable interventions), to achieve a final sample size of N=120 (N=60 per group). This sample size has been calculated to achieve >80% statistical power to detect effects comparable to previous trials (Caller et al., 2016; Streltzov et al., 2022) on the primary outcome measure (QoLIE-31), assuming alpha = 0.05 and standard deviation = 16.6 (from baseline sample reported in Streltzov et al., 2022). As formal estimates of minimum clinically important differences on the QoLIE-31 vary considerably, we have opted to take a mid-point estimate of 8.50 points, based on key studies (Borghs et al., 2012; Wiebe et al., 2002), which closely aligns with the observed QoLIE-31 change reported for the most recent HOBSCOTCH trial (Streltzov et al., 2022).

Quantitative primary and secondary outcomes will be analysed using appropriate statistical software (i.e., SPSS, SAS, STATA, and Excel). For the RCT, linear mixed models will be used to examine the differences between groups (treatment versus waitlist control) on outcome measures across the assessment time-points (up to 4 in total) and adjusting for relevant covariates. We will engage the support of a biostatistician and health economist, as required. Analyses will be conducted as a comparison of two groups, blind to specific group allocation.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Recruitment hospital [1] 30294 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 30295 0
Westmead Hospital - Westmead
Recruitment postcode(s) [1] 46697 0
2050 - Camperdown
Recruitment postcode(s) [2] 46698 0
2145 - Westmead

Funding & Sponsors
Funding source category [1] 321325 0
Government body
Name [1] 321325 0
NSW Health Translational Grants Scheme (Round 8; Grant No. DG24/7601)
Country [1] 321325 0
Australia
Primary sponsor type
Government body
Name
Sydney Local Health District
Address
Country
Australia
Secondary sponsor category [1] 324108 0
None
Name [1] 324108 0
Address [1] 324108 0
Country [1] 324108 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319858 0
Sydney Local Health District Ethics Review Committee (RPAH Zone)
Ethics committee address [1] 319858 0
Ethics committee country [1] 319858 0
Australia
Date submitted for ethics approval [1] 319858 0
23/01/2026
Approval date [1] 319858 0
10/04/2026
Ethics approval number [1] 319858 0
X26-0023

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148638 0
A/Prof Kylie Radford
Address 148638 0
Royal Prince Alfred Hospital, 50 Missenden Road, Camperdown NSW 2050
Country 148638 0
Australia
Phone 148638 0
+61 2 9515 2476
Fax 148638 0
Email 148638 0
Contact person for public queries
Name 148639 0
Philip Edwards
Address 148639 0
Royal Prince Alfred Hospital, 50 Missenden Road, Camperdown NSW 2050
Country 148639 0
Australia
Phone 148639 0
+61 2 9515 7816
Fax 148639 0
Email 148639 0
Contact person for scientific queries
Name 148640 0
Dr Sau Chi Cheung or A/Prof Kylie Radford
Address 148640 0
Royal Prince Alfred Hospital, 50 Missenden Road, Camperdown NSW 2050
Country 148640 0
Australia
Phone 148640 0
+61 2 9515 7816
Fax 148640 0
Email 148640 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
• Published results
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
At the end of the study
To:
A finite period of: 15 years
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: Please email co-PIs A/Prof Kylie Radford ([email protected]) and/or Dr Sau Chi Cheung (sauchi.cheung@health,nsw.gov.au)

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.